Nexalin Technology, Inc. announced that it has commenced sales of its second generation (Gen-2), 15 milliamp (mA) neurostimulation device into a new mental health center in Oman, dedicated to the use of Nexalin?s neurostimulation device for the treatment of patients with substance abuse disorder (SUD). The new clinic opened and commenced treatment of patients with Nexalin?s Gen-2 neurostimulation device following a successful evaluation and inspection of the facility by the Sultanate of Oman?s Ministry of Health, which ensures strict quality standards and adherence to established and robust guidelines and regulations.